The treatment marks the only targeted oral treatment in patients with non–small cell lung cancer with epidermal growth factor ...

Access to and affordability of immune checkpoint inhibitors, which can be lifesaving if patients receive them on time and ...

For the second time in under 3 weeks, the FDA has approved treatment for the inherited genetic disorder characterized by ...

Coverage from “Tech Innovations in Oncology,” presented June 19, 2025, by Tennessee Oncology in Nashville, Tennessee. First ...

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) treated with venetoclax plus obinutuzumab experienced significantly higher rates of serious infections compared ...

Panelists discuss how patient perspectives on new therapies center around clinically meaningful outcomes and survival while balancing individual risk tolerance, with some patients willing to accept ...

A panelist discusses how the ASCERTAIN-V study demonstrated that an all-oral combination of decitabine-cedazuridine plus venetoclax achieved a 47% complete response rate and 15.5-month median overall ...

Panelists discuss how exciting ongoing research efforts are expanding similar gene therapy technologies to other muscular dystrophies like FSHD and myotonic dystrophy, using strategies to knock down ...

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...

Avoiding downstream testing ultimately makes it cheaper for whoever is footing the bill, says Merrill H. Stewart, MD, Ochsner Health.

Panelists discuss how chronic neuroinflammation involves distinct mechanisms from acute relapses—including microglial ...

Alexander I. Spira, MD, PhD, of The US Oncology Network, discusses findings from the COCOON trial that show prophylactic ...